Madeleine Willkom

530 total citations
8 papers, 409 citations indexed

About

Madeleine Willkom is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Madeleine Willkom has authored 8 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Infectious Diseases, 4 papers in Virology and 4 papers in Epidemiology. Recurrent topics in Madeleine Willkom's work include HIV Research and Treatment (4 papers), HIV/AIDS drug development and treatment (4 papers) and HIV/AIDS Research and Interventions (2 papers). Madeleine Willkom is often cited by papers focused on HIV Research and Treatment (4 papers), HIV/AIDS drug development and treatment (4 papers) and HIV/AIDS Research and Interventions (2 papers). Madeleine Willkom collaborates with scholars based in United States and Czechia. Madeleine Willkom's co-authors include David J. Erle, Gabriele Grünig, Rajeev Venkayya, David B. Corry, Maggie Lam, Gabriel Birkuš, Hal Martin, Kirsten White, Ross Martin and Christian Frey and has published in prestigious journals such as PLoS ONE, Antimicrobial Agents and Chemotherapy and Journal of Hepatology.

In The Last Decade

Madeleine Willkom

8 papers receiving 405 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Madeleine Willkom United States	7	168	148	116	104	75	8	409
Isidro Sanz Pérez Spain	9	114 0.7×	78 0.5×	72 0.6×	38 0.4×	90 1.2×	15	368
Sven Philip Aries Germany	8	122 0.7×	36 0.2×	105 0.9×	113 1.1×	86 1.1×	12	347
Thomas Wendland Switzerland	14	109 0.6×	79 0.5×	122 1.1×	187 1.8×	204 2.7×	18	657
Barbara Hahn United States	10	105 0.6×	33 0.2×	106 0.9×	81 0.8×	106 1.4×	12	353
K Krätzel Germany	6	50 0.3×	52 0.4×	110 0.9×	181 1.7×	40 0.5×	6	447
Karin Frutig Switzerland	11	72 0.4×	109 0.7×	68 0.6×	258 2.5×	102 1.4×	12	623
Karol Serwin Poland	10	86 0.5×	26 0.2×	41 0.4×	41 0.4×	60 0.8×	37	282
Zoran Popmihajlov United States	14	58 0.3×	23 0.2×	62 0.5×	154 1.5×	257 3.4×	33	509
Yan‐Mei Jiao China	13	164 1.0×	13 0.1×	161 1.4×	167 1.6×	94 1.3×	48	425
C. Smacchia Italy	8	118 0.7×	50 0.3×	43 0.4×	34 0.3×	138 1.8×	10	400

Countries citing papers authored by Madeleine Willkom

Since Specialization

Citations

This map shows the geographic impact of Madeleine Willkom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Madeleine Willkom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Madeleine Willkom more than expected).

Fields of papers citing papers by Madeleine Willkom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Madeleine Willkom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Madeleine Willkom. The network helps show where Madeleine Willkom may publish in the future.

Co-authorship network of co-authors of Madeleine Willkom

This figure shows the co-authorship network connecting the top 25 collaborators of Madeleine Willkom. A scholar is included among the top collaborators of Madeleine Willkom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Madeleine Willkom. Madeleine Willkom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Acosta, Rima, Madeleine Willkom, Kristen Andreatta, et al.. (2020). Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. JAIDS Journal of Acquired Immune Deficiency Syndromes. 85(3). 363–371. 20 indexed citations

Jordan, Robert, Tetsuya Kobayashi, Ryan A. Dick, et al.. (2019). Anti-HBV activity of retinoid drugs in vitro versus in vivo. Antiviral Research. 169. 104538–104538. 5 indexed citations

Andreatta, Kristen, Madeleine Willkom, Ross Martin, et al.. (2019). Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. Journal of Antimicrobial Chemotherapy. 74(12). 3555–3564. 49 indexed citations

Acosta, Rima, Madeleine Willkom, Ross Martin, et al.. (2019). Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks. Antimicrobial Agents and Chemotherapy. 63(5). 41 indexed citations

Barauskas, Ona, Weimei Xing, Madeleine Willkom, et al.. (2017). Biochemical characterization of recombinant influenza A polymerase heterotrimer complex: Polymerase activity and mechanisms of action of nucleotide analogs. PLoS ONE. 12(10). e0185998–e0185998. 7 indexed citations

Tam, Danny, Ryan A. Dick, T.C. Appleby, et al.. (2017). Antiviral activity of GS-5801, a liver-targeted prodrug of a lysine demethylase 5 inhibitor, in a hepatitis B virus primary human hepatocyte infection model. Journal of Hepatology. 66(1). S690–S691. 31 indexed citations

Birkuš, Gabriel, Rujuta A. Bam, Madeleine Willkom, et al.. (2015). Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors. Antimicrobial Agents and Chemotherapy. 60(1). 316–322. 61 indexed citations

Venkayya, Rajeev, Maggie Lam, Madeleine Willkom, et al.. (2002). The Th2 Lymphocyte Products IL-4 and IL-13 Rapidly Induce Airway Hyperresponsiveness Through Direct Effects on Resident Airway Cells. American Journal of Respiratory Cell and Molecular Biology. 26(2). 202–208. 195 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact